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Emerging infectious diseases continue to be of a significant
importance worldwide with the potential to cause major
outbreaks and global pandemics. In 2002, the world had
witnessed the appearance of the severe acute respiratory
syndrome coronavirus (SARS-CoV) in China.1,2 And about a
decade later, a new and emerging coronavirus was described
in a patient fromSaudi Arabia.3,4 The viruswas identified as a
novel coronavirus and later was named the Middle East
respiratory syndrome coronavirus (MERS-CoV).5 These two
coronaviruses shared multiple similarities in the epidemiol-
ogy, clinical presentations, and posed challenges in preven-
tion and management.6,7 For any new emerging zoonotic
pathogen, there are five stages in the evolution to cause
diseases limited to humans. In stage 1, the pathogen is
confined to the animal host; in stage 2, human infections
occur as a result of animal contacts; in stage 3, there is a
limited human-to-human transmission; stage 4, there are
multiple outbreaks with human-to-human transmission;
and stage 5, infections occur within humans.8 In this review,
we describe the epidemiology, clinical features, and outcome
of both SARS and MERS-CoV.
The SARS-CoV and MERS-CoV
SARS-CoV andMERS-CoV are enveloped positive strand RNA
betacoronaviruses. The first coronavirus was isolated from
humans in 1965 and was cultivated on human ciliated
embryonal tracheal cells.9 Coronaviruses are enveloped,
and positive stranded RNA viruses classified as a family
within the Nidovirales order. There are four genera: α, β,
gamma, and delta, and human coronaviruses belong to the α
or the β genera.10 In 2002, SARS-CoVoutbreak was described
and the virus was 50 to 60% identical and distantly related to










Abstract Emerging infectious diseases continue to be of a significant importanceworldwidewith the
potential to causemajoroutbreaks andglobal pandemics. In2002, theworldhadwitnessed
the appearance of the severe acute respiratory syndrome coronavirus in China which
disappeared abruptly within 6 months. About a decade later, a new and emerging novel
coronavirus named the Middle East respiratory syndrome coronavirus (MERS-CoV) was
described in a patient from Saudi Arabia. These two coronaviruses shared multiple
similarities in the epidemiology, clinical presentations, and posed challenges in its
prevention and management. Seven years since its discovery, MERS-CoV continues to
be a lethal zoonotic pathogen capable of causing severe pneumonia with high case fatality
rates and the ability to cause large health care-associated outbreaks.
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to cause disease in macaques with a similar spectrum of
disease.12 While the MERS-CoV belongs to lineage C beta-
coronavirus and emerged in September 2012 and continuous
to cause sporadic cases and clusters of disease mostly in the
Arabian Peninsula.13
SARS Outbreak Evolution and Clinical
Characteristics
The initial description of the SARS outbreak was announced in
November 2002 throughnon-official reports of the occurrence
of an outbreak of respiratory illness in Guangdong Province,
China,14 and few months later, this was reported to the
World Health Organization (WHO). Analysis of the virus
showedapoint-source outbreak.15Thediseasewas recognized
due to the occurrence of a cluster of atypical pneumonias
occurring in Vietnam, Hong Kong, Canada, United States, and
Singapore.1,16–23 All cases were linked to a patient who stayed
in hotel M in Hong Kong, and subsequently, patients traveled
fromHong Kong to Ireland, Vietnam, Singapore, United States,
and Canada.24 This outbreak involved 30 countries in 6 con-
tinentsand causeda total of 8,098 caseswitha case fatality rate
of9.5%.25Theclinical spectrumof thedisease ranged frommild
to severe disease requiring mechanical ventilation.26 The
clinical picture followed an initial febrile illness, followed by
aperiod of improvement then a clinical deterioration.27–29The
need for intensive care unit (ICU) care was described in 17 to
30% of SARS patients.28–30 In another study, 15% of SARS
patients required mechanical ventilation.27 Patients also had
extra-respiratory symptoms such as diarrhea.31 It was inter-
esting tonote thathealthcareworkers (HCWs) constituted21%
ofall SARScases.32–34Thediseasewasassociatedwith10%case
fatality rate,35 and the presence of diabetes mellitus and other
comorbidities was associated with increased fatality rates.30
SARSwas thought to cause milder disease in children with no
fatalities.36 One reason for the rapid spread of SARS was the
occurrence of superspreaders.35 Superspreading event is de-
scribed as the ability of certain individuals to infect a dispro-
portionately large number of secondary patients relative to a
typical infectious individual.
The origin of the SARS virus is thought to be animal and a
similar virus was isolated from Himalayan palm civets
(Paguma larvata), raccoon dogs (Nyctereutes procyonoides),
and from a Chinese ferret badger (Melogale moschata).37 In
addition, antibodies against SARS-CoV were found among
wild animal traders in Guangdong Province.37,38 A seroprev-
alence of 72.7% was well known among those with trading
history involving P. larvata.38 Although most patients with
SARS had symptomatic disease, there are few seroprevalence
studies and one study showed that 124 (12%) of 1,030
individuals were positive by ELISA and 0.19% by the SARS-
specific immunofluorescence assay (IFA).39 In another study,
seroprevalence amongHCWswas 2.3%40 and ameta-analysis
showed an overall seroprevalence of 0.10%.41 There were no
approved therapeutic or preventative options for SARS,while
a variety of therapeutic agents were used.42 SARS human
cases disappeared abruptly by June 2003 with no approved
vaccine or therapeutic agents developed or applied.
MERS-CoV Evolution and Origin of the Virus
Thefirst case ofMERS-CoVwas reported in a businessmanwho
lived in Bisha, Kingdomof Saudi Arabia (KSA)who presented to
health carewith pneumonia in early June 2012 and on transfer
toahospital in Jeddah,herapidlysuccumbed todeathwithin10
days of diagnosis with multiorgan failure. The virus was later
isolated and reported in September 2012 as the newly emerg-
ing MERS-CoV. As of January 2020, there have been a total of
2,468 cases of human MERS-CoV cases reported to WHO from
27 countries. More than 80% of cases have been reported from
the Arabian Peninsula with KSA being the most affected
country. There have been 851 reported mortalities with an
overall case fatality rate of MERS-CoV estimated at 35%
(►Fig. 1). TheexactoriginofMERS-CoV isnotknown.However,
MERS-CoV is likely to have originated from bats based on the
isolation of other lineage C β-coronaviruses closely related to
MERS-CoVand the isolationofa bat coronavirus that resembles
MERS-CoV. Throat swabs,urine, feces, and serumsampleswere
collected fromwildbats in theKSA including theareawherethe
firstMERS-CoVpatienthad livedandworked.A190-nucleotide
fragment of the RNA-dependent RNA polymerase region of
MERS-CoV genome was detected in one fecal pellet from an
Egyptian tomb bat (Taphozous perforates).43 The amplified
sequence was identical to that of the MERS-CoV sequence
from the first index human case.43 The one-humped drome-
daries (Camelus dromedarius) had been linked to MERS-CoV
(►Fig. 2). Multiple studies showed high prevalence of MERS-
CoV antibodies in dromedary camels in the Arabian Peninsula,
North Africa, and Eastern Africa.44–50 In addition, studies have
shown thatMERS-CoVantibodieswere present in stored camel
sera as early as early 1990s, suggesting the presence of MERS-
CoV in dromedaries for over 20 years before itsfirst description
in humans.50–52 MERS-CoV antibodies were detected more
commonly among camels> 2 years of age compared with
younger camels.46,52–54 In addition, MERS-CoV was detected
from respiratory tract samples by reverse transcriptase poly-
merase chain reaction (RT-PCR) in oronasal and fecal samples
from dromedary camels in the Arabian Peninsula.52–58 In
contrast to the MERS-CoV antibodies, juvenile camels shed
more MERS-CoV as detected by PCR.52–55 In addition, viable
MERS-CoV was isolated in cell cultures from nasal and fecal
samples from dromedary camels.54,57,59–61 There had been
studies documenting the isolation of similar and near-identical
MERS-CoV strains from epidemiologically linked humans and
dromedarycamels.61–63 Inaddition, sequenceof theMERS-CoV
spike, ORF3–4a, and nucleocapsid regions were identical from
asymptomatic contacts and their camels.64 The most recent
common ancestor of all humanMERS-CoVwas found phyloge-
netically to date to the end of the year 2010.65 In addition,
animal reservoir is geographically dispersed.66,67
Clinical Features and Laboratory Findings
The clinical and laboratory presentations of SARS-CoV and
MERS-CoVaresimilarwithsomeminordifferenceshighlighted
in►Table 1. TheclinicalpictureofMERS-CoVcases ranges from
asymptomatic to severe cases. In many cases, the presenting
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symptoms are respiratory and 33% of patients have gastroin-
testinal symptoms such as vomiting and diarrhea.68–73 Most
hospitalizedMERS-CoVpatientspresentwith fever, cough, and
shortness of breath with clinical and radiological evidence of
pneumonia.70–72,74 It seems that severe disease is a character-
istic of primary cases, immunocompromised, and those with
underlying comorbidities namely diabetes, kidney, and heart
disease. In severe cases, there are multiple complications
including respiratory and renal failure, acute liver injury,
cardiac arrhythmias, and coagulopathy.69,70,73,75 There are
few studies which showed no predictive signs or symptoms
todifferentiate patientswith community-acquiredpneumonia
from those with MERS-CoV infection.72,76 The median
incubation period was 5.2 days (95% confidence interval
[CI], 1.9–14.7), and the serial interval was 7.6 days (95% CI,
2.5–23.1).69Themediantimetohospitalization, ICUadmission,
mechanical ventilation, and death were 5, 7, and 11 days,
respectively.69,77 MERS-CoV carries a high case fatality rate
(28.6–63.6%) specially among elderly patients with several
comorbidities, while in young healthy patients, they present
with mild to no symptoms.71,78 One study found a lower case
fatality rate similar to the rate reported in patients from South
Korea of 9%.79,80 The variability of the case fatality ratesmay be
related to host factors, associated comorbidities, care provided,
and yet unidentified factors.78 In addition, the case fatality rate
is inversely related to the percentage of asymptomatic cases as
the percentage of these patients increased to 29%, and the case
fatality rate decreased to 30%.70,71,77,81–83 In addition, the case
fatality rate is higher among critically ill patients76,78–80 com-
paring between MERS-CoV and non-MERS-CoV patients in
relation to age, clinical, and laboratory features.72,76,84–86 In
KSA,extensive testing forMERS-CoVisbeingdoneover thepast
6 years with> 50,000 patients presenting to emergency care
with respiratory symptoms being screened forMERS-CoVeach
year with a very low yield of 0.7% being positive.87 This
excessive testing is applied in combinationwith a visual triage
in all emergency rooms of all health care facilities (governmen-
tal and private) utilizing a clinical score cutoff of> 4 forMERS-
CoV infection showing sensitivity and specificity of 74.1 and
18.6%, respectively, in predicting MERS-CoV diagnosis.88
Predictors of 30-day mortality included factors such as
age> 65 years, being a non-HCW, the presence of preexisting
comorbidities, presentation with severe disease, hospital-
acquired infections, and corticosteroid use.70,89–91 The use of
continuous renal replacement therapy and extracorporeal
membrane oxygenation (ECMO) were additional risk factors
for increased fatality.91–93 However, one study showed
ECMO lowering in-hospital death.94
Fig. 2 Camels: a possible intermediary source of Middle Eastern
respiratory syndrome coronavirus.
Fig. 1 Epicurve of confirmed global cases of MERS-CoV from September 2012 to July 16, 2019. MERS-CoV, Middle East respiratory syndrome
coronavirus; WHO, World Health Organization.
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Table 1 Comparison of demographic, clinical, and laboratory features between MERS-CoV and SARS-CoV
MERS-CoV8,36–39 SARS-CoV1,28,40
Date of first case report (place) April 2012 (Jordan) November 2002 (China)
June 2012 (first KSA case)
Incubation period Mean: 5.2 d (95% CI: 1.9–14.7) Mean: 4.6 d (95% CI: 3.8–5.8)
Range: 2–13 d Range: 2–14 d




Age (y): range, median Range: 1–94; median: 50 Range: 1–91; mean: 39.9
Mortality
CFR—overall 41.8% 9.6%
CFR in patients with comorbidities 13.3% 1–2%
Time from onset to death Median 11.5 d Mean 23.7d
Sex (M, F) M: 64.5%, F: 35.5% M: 43%, F: 57%
Presenting symptoms

















Chronic renal disease 13% 2–6%





Viral hepatitis Not known 27%
Laboratory results
CXR abnormalities 100% 94–100%
Lymphopenia (<1.5 109/L) 32% 68–85%
Leukopenia (<4.0 109/L) 14% 25–35%
(Continued)
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The diagnosis of MERS-CoV infection relies on the confirma-
tion by real-time reverse transcriptase PCR of respiratory
tract samples. Lower respiratory samples provide better
yield and is the sample source of choice for testing.95,96
However, a single negative test should not rule out infection
and a repeat testing is indicated as some patients may have
intermittent positive tests.97 Serologic testing for MERS-CoV
utilizes IFA, serum neutralization, or protein microarray
assays to detect MERS-CoV antibodies.98 The utility of sero-
diagnosis relies on two serum samples taken 14 days ormore
apart. Serodiagnosis begins with a screening ELISA or IFA and
a confirmatory neutralization assay.99–101 Testing for MERS-
CoV by PCR detected the virus in the patient serum, urine,
and feces but at a much lower level than those found in the
lower respiratory tract.102 Patients withMERS-CoV infection
had abnormal laboratory findings including: leukopenia,
lymphopenia, thrombocytopenia, and elevated hepatic
enzymes.68,71,72,76,103 A risk analysis showed that the fol-
lowing were associated with increased risk of death: pres-
ence of comorbidity (relative risk [RR]¼ 3), male gender
(RR¼ 1.6), exposure to dromedary camels (RR¼ 1.6), and
consumption of camel milk (RR¼ 1.5).104 Overall, over the
past 7 years, 50% of MERS-CoV cases reported to WHO were
associated with human-to-human transmission in hospitals.
Among 61MERS-CoV patients presenting withMERS-CoV in
2017, 9 (15%) were associated with a hospital outbreak, 10
(16%) were household contacts, and 42 (69%) were sporadic
cases. Of the 42 sporadic cases, 50% had camel contact.105 In
an outbreak investigation of a cluster of MERS cases in a
nonhealth care–associated setting, 18 (2.2%) of 828 contacts
were positive for MERS-CoV infections.106 This rate was
similar to household contact study of 4.3%.101
Intrahospital Transmission
Health care–associated infection is the hallmark of the trans-
mission of MERS-CoV between patients and from patients to
HCWs.69,70,74,81,107–123 Of the factors contributing to intra-
hospital transmission is the occurrence of superspreading
events. In the outbreak in the Republic of Korea, three patients
were epidemiologically connected to 73% of the transmissions
and each infected 23, 28, and 85 individuals.124 In addition,
superspreader phenomena also occurred in the first reported
outbreak in Al-Hasa, Saudi Arabia.69 A recent systematic
review outlined the contributing factors to health care–asso-
ciatedMERS-CoV transmissions and included: absent physical
barriers between beds, inadequate isolation of suspected
MERS patients, lack of isolation and negative pressure rooms,
unfamiliarity and underrecognition of MERS infection, insuf-
ficient compliance with infection control measures, aerosol
generatingprocedures,presenceofmultiplefriendsandfamily
members in the patient’s room, and the phenomena of “medi-
cal shopping.”125 HCWs may act as contributors to the spread
of MERS-CoV infection. In one study, MERS-CoV PCR was
positive in 4.5% among exposed HCWs126 and another study
showed 15 (1.3%) of 1,169 HCWs were positive by PCR and 5
(0.68%) of 737 HCWs were positive by serology.127 Other
studies showed none of 38 HCWs was positive by serology128
and none of 48 contactswaspositive.129 In Korea, 36 (19.9%) of
181 confirmed MERS-CoV cases were HCWs.130 However,
studies had showed that most positive HCWs were asymp-
tomatic or had mild disease.131 Although major hospital out-
breakswere thought to be linked to intrahospital transmission
ofMERS-CoV,MERS-CoVgenomesequence in these outbreaks
showed multiple introductions of the virus with human-to-
human transmissions.66,67,69 Therewere three distinctMERS-
CoV genotypes.67
Seasonality of MERS-CoV
The emergence of MERS-CoV had led to many speculations
regarding the seasonality of this disease and initially
thought to occur mostly in March–May and September–
November.81,132,133 One reason for such a significant in-
crease in April–May 2014 was a large outbreak in Jeddah,
Saudi Arabia.107 However, seasonal variation may be the
result of seasonality in the calving of dromedaries in
November and March.10,44,46,48,52,55,77,82,83,134 Such a con-
cept was studied and it was found that the prevalence of
MERS-CoV was higher in camels in the winter (71.5%) than
the summer season (6.2%).135 Looking at all MERS-CoV
cases from 2012 to 2016, the mean monthly cases were
Table 1 (Continued)
MERS-CoV8,36–39 SARS-CoV1,28,40
Thrombocytopenia (<140 109/L) 36% 40–45%
Elevated LDH 48% 50–71%
Elevated ALT 11% 20–30%
Elevated AST 14% 20–30%
Ventilatory support required 80% 14–20%
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CFR, case fatality rate; CI, confidence interval; CXR, chest X-ray; KSA,
Kingdom of Saudi Arabia; LDH, lactate dehydrogenase; MERS-CoV; Middle East respiratory syndrome coronavirus; SARS-CoV, severe acute
respiratory syndrome coronavirus.
Source: Reproduced with permission from Hui et al.161
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higher in the winter and summer months.136 Evaluation of
cases from January 2013 and December 2017 included a
total of 2,025 cases and showed a noteworthy decrease in
the annual cases in 2016 to 2017.137 Of all the 2,025 cases,
38.2% occurred in the Spring and 36.4% occurred in the
Summer.137 However, there was no variation on the number
of cases per year, and either per month or per season.137
Therapeutic Options
Currently, there is no approved therapy for MERS-CoV infec-
tion. Studies showed superiority of interferon (IFN)-β com-
pared with other IFN types138 and that polyethylene glycol
IFN-α had excellent cytopathic inhibitory effect.139 In addi-
tion, the combination of INF-α2b and ribavirin showed
augmentation of action and lower concentrations of IFN-
α2b and ribavirin were required.140 However, the data from
clinical use of these two agents in retrospective studies
showed no therapeutic advantages of these on survival of
patients.42,141–145 A retrospective analysis showed that
using INF to treat patients with positive MERS-CoV RT-PCR
was associatedwith a case fatality rate of 90% comparedwith
44% in thosewith negativeMERS-CoVRT-PCR test.68Another
study showed survival rates of 78.3, 75, and 68.4% using IFN-
β, IFN-α, and ribavirin, respectively.146 The use of the antire-
troviral therapy forMERS-CoVwas tried using pegylated IFN,
ribavirin, and lopinavir/ritonavir143 and another eight
patients received mycophenolate mofetil and the latter
patients survived.146 A randomized controlled trial using a
combination of lopinavir–ritonavir and IFN-β1b is being
conducted.147
Seroprevalence of MERS-CoV
AlthoughMERS-CoV PCR testing is themainmethodology for
the diagnosis of MERS-CoV infection, serologic tests con-
firmed 8 (6.4%) of 124 Jordanian contacts who were posi-
tive.119 Seroprevalence of 356 abattoir workers and blood
donors found that 8 (2.2%) were weakly positive by immu-
nofluorescence assay (IFA), and none was had positive neu-
tralization titers.148 A seroprevalence study found none of
268 children with respiratory tract infections to be posi-
tive.149 In an evaluation of 280 household contacts, 12 (4.3%)
were probable cases by serology.101 However, in a popula-
tion-based surveyof 10,000 samples, the seroprevalencewas
0.15% and the camel shepherd and abattoir workers had 17-
and 26-fold increase in seroprevalence in comparison to the
general population.150
Infection Control
MERS-CoV is stable in the environment and can survive on
plastic and steel for up to 48 hours at lower temperature and
humidity. However, MERS-CoV is less viable at higher tem-
perature and humidity.151 This finding was confirmed by
another study where a temperature of 65°C had a strong
negative effect on viral infectivity compared with a temper-
ature of 25°C.152 In the hospital setting, WHO advocates
contact and droplet precautions with airborne isolation
when dealing with aerosol-generating procedures.153,154
However, both the United States and the European Centre
for Disease Prevention and Control recommend the use of
airborne infection isolation precautions.155
MERS and Camel Connections
In a recent study from Egypt, Senegal, Tunisia, Uganda,
Jordan, Saudi Arabia, and Iraq, MERS-CoV was detected in
camels using either PCR or serology.156 The positivity rate
using PCR ranged from 0% in Uganda, Jordan, and Iraq to
3.1% in Saudi Arabia, 5.5% in Senegal, and 8.2% in Egypt.156 It
was shown that seropositivity is very high (84.5%) among
tested camels compared with PCR positivity of 3.8%.157
Studies from Saudi Arabia showed either no significant
difference in seropositivity of MERS-CoV in camels in
different regions156 or had detected variable seropositivity
to MERS-CoV (37–100%).158 It is worth mentioning that
Somalia and Sudan are the main source of imported camels
into Saudi Arabia.156
The seroprevalence of MERS-CoV is lower (30.3%) in
juvenile camels (<2 years of age) compared with adult
camels (82.6%)156 as described in the previous studies.53
Also, the detection rate of MERS-CoV RNA by PCR is higher
in adults (16.1%) compared with juvenile camels (1.7%).156
What is unusual is the ability of MERS-CoV to causes
reinfection of camels in the presence of antibodies.56,156
Another important finding of MERS-CoV in camels is that
camels rarely show signs of infection.156,159 Although it has
been postulated that drinking camel milk is one of the key
sources of infection in the Arabian peninsula, a study found
no MERS-CoV in the urine of naturally infected camels.160
Conclusion
Emerging respiratory viruses, specially MERS-CoV, continue
to challenge the public health infrastructure of countries of
the Arabian Peninsula with the risk of transmission and
outbreaks in other countries though travel. Although it is
still debated by some, bats appear to be the common natural
source of both SARS and MERS. There are considerable
similarities in the clinical features of both MERS-CoV and
SARS-CoV, but MERS tends to progress much faster to
respiratory failure than SARS. Although SARS-CoV clinical
cases disappeared since mid-2003, both MERS-CoV and
SARS-CoV are still listed as priority pathogens by the WHO
research and development blueprint. The case fatality rate of
MERS-CoV is much higher and likely related to older age and
comorbid illness of the sporadic cases. Several gaps continue
in our knowledge about disease prevention and treatment,
and more studies are needed to understand the pathogene-
sis, viral kinetics, mode of disease transmission, any other
intermediary source, and treatment options ofMERS to guide
public health infection control measures and treatment.
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